Amalgamated Bank Cerevel Therapeutics Holdings, Inc. Transaction History

Amalgamated Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$38.96 - $42.75 $92,919 - $101,958	2,385 Added 100.0%	4,770 $195,000
Q1 2024 Apr 23, 2024	SELL	$40.88 - $43.27 $312,404 - $330,669	-7,642 Reduced 76.21%	2,385 $101,000
Q4 2023 Feb 06, 2024	BUY	$20.27 - $42.44 $16,398 - $34,333	809 Added 8.78%	10,027 $425,000
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $26,815 - $39,696	1,122 Added 13.86%	9,218 $293,000
Q1 2023 May 02, 2023	SELL	$22.82 - $35.32 $33,362 - $51,637	-1,462 Reduced 15.3%	8,096 $197,000
Q4 2022 Feb 10, 2023	BUY	$25.35 - $31.96 $21,141 - $26,654	834 Added 9.56%	9,558 $301,000
Q3 2022 Nov 09, 2022	BUY	$25.5 - $41.42 $3,519 - $5,715	138 Added 1.61%	8,724 $247,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $40,270 - $72,553	1,953 Added 29.44%	8,586 $227,000
Q1 2022 Jun 30, 2022	SELL	$23.5 - $35.38 $11,679 - $17,583	-497 Reduced 6.97%	6,633 $232,000
Q4 2021 Feb 15, 2022	BUY	$29.21 - $44.64 $321 - $491	11 Added 0.15%	7,130 $231,000
Q3 2021 Oct 29, 2021	BUY	$21.26 - $38.85 $151,349 - $276,573	7,119 New	7,119 $210,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.